Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum--use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI.

OBJECTIVE The purpose of this article is to address radiation necrosis, pseudoprogression, and pseudoresponse relative to high-grade gliomas and evaluate the role of conventional MRI and, in particular, dynamic susceptibility contrast-enhanced perfusion MRI in assessing such treatment-related changes from tumor recurrence. CONCLUSION Posttreatment imaging assessment of high-grade gliomas remains challenging. Familiarity with the expected MR imaging appearances of treatment-related change and tumor recurrence will help distinguish these entities allowing appropriate management.

[1]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Chamberlain.  Pseudoprogression in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Namkug Kim,et al.  Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging. , 2013, Radiology.

[4]  Philip H. Gutin,et al.  Radiation Injury to the Nervous System , 1991 .

[5]  A. Friedman,et al.  Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas , 2008, Clinical Cancer Research.

[6]  Amy Y. Chen,et al.  Pitfalls in the staging squamous cell carcinoma of the hypopharynx. , 2013, Neuroimaging clinics of North America.

[7]  Max Wintermark,et al.  Perfusion MRI: the five most frequently asked clinical questions. , 2013, AJR. American journal of roentgenology.

[8]  Ricardo J. Komotar,et al.  Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? , 2013, Journal of Neuro-Oncology.

[9]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[10]  Susan Chang,et al.  Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging , 2009, Current neurology and neuroscience reports.

[11]  G. Tedeschi,et al.  Recurrent glioblastoma multiforme versus radiation injury: a multiparametric 3-T MR approach , 2014, La radiologia medica.

[12]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[13]  P Van Tassel,et al.  Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. , 2000, Radiology.

[14]  Michael A. Finn,et al.  Transient postictal MRI changes in patients with brain tumors may mimic disease progression. , 2007, Surgical neurology.

[15]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[16]  Achim Seeger,et al.  Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease. , 2013, Academic radiology.

[17]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[18]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G Johnson,et al.  Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. , 1999, Radiology.

[20]  P. Box.  Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression , 2005 .

[21]  R. Jensen,et al.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target , 2009, Journal of Neuro-Oncology.

[22]  Hyun-Cheol Kang,et al.  Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53 , 2011, Journal of Neuro-Oncology.

[23]  R M Weisskoff,et al.  Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.

[24]  T. Phillips,et al.  Leibel and Phillips textbook of radiation oncology , 2010 .

[25]  M. Mehta,et al.  Pseudoprogression after glioma therapy: a comprehensive review , 2013, Expert review of neurotherapeutics.

[26]  O. Chinot,et al.  Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[28]  M. Berger,et al.  Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2009, Radiology.

[29]  Namkug Kim,et al.  Histogram Analysis of Intravoxel Incoherent Motion for Differentiating Recurrent Tumor from Treatment Effect in Patients with Glioblastoma: Initial Clinical Experience , 2014, American Journal of Neuroradiology.

[30]  Glyn Johnson,et al.  Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. , 2002, Radiology.

[31]  D. Kong,et al.  Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status , 2011, American Journal of Neuroradiology.

[32]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M Takahashi,et al.  Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. , 2000, AJNR. American journal of neuroradiology.

[35]  P. Wen,et al.  A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.

[36]  William D Rooney,et al.  Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. , 2011, International journal of radiation oncology, biology, physics.

[37]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[38]  K. Kang,et al.  Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI , 2010, Clinical Neurology and Neurosurgery.

[39]  M. Shiroishi,et al.  Brain tumors: a multimodality approach with diffusion-weighted imaging, diffusion tensor imaging, magnetic resonance spectroscopy, dynamic susceptibility contrast and dynamic contrast-enhanced magnetic resonance imaging. , 2013, Magnetic resonance imaging clinics of North America.

[40]  T. Mikkelsen,et al.  A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) , 2008 .

[41]  G. Jahng,et al.  Investigation of Perfusion-weighted Signal Changes on a Pulsed Arterial Spin Labeling Magnetic Resonance Imaging Technique: Dependence on the Labeling Gap, Delay Time, Labeling Thickness, and Slice Scan Order , 2013 .

[42]  C. Suh,et al.  Prediction of Pseudoprogression in Patients with Glioblastomas Using the Initial and Final Area Under the Curves Ratio Derived from Dynamic Contrast-Enhanced T1-Weighted Perfusion MR Imaging , 2013, American Journal of Neuroradiology.

[43]  Ucla Medical.  MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006 .

[44]  Timothy D Johnson,et al.  Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  B R Rosen,et al.  Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. , 1996, AJNR. American journal of neuroradiology.

[46]  A G Sorensen,et al.  Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma , 2011, American Journal of Neuroradiology.

[47]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[48]  K. Schmainda,et al.  Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. , 2008, Radiology.

[49]  M. Gilbert,et al.  Cerebral Radiation Necrosis , 2003, The neurologist.

[50]  A. Sorensen,et al.  Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. , 2002, AJR. American journal of roentgenology.

[51]  Mark E Mullins,et al.  Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. , 2005, AJNR. American journal of neuroradiology.

[52]  Tracy T Batchelor,et al.  T1- and T2*-Dominant Extravasation Correction in DSC-MRI: Part II—Predicting Patient Outcome after a Single Dose of Cediranib in Recurrent Glioblastoma Patients , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[53]  Sotirios Bisdas,et al.  Distinguishing recurrent high-grade gliomas from radiation injury: a pilot study using dynamic contrast-enhanced MR imaging. , 2011, Academic radiology.

[54]  Jianhui Zhong,et al.  Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. , 2010, Radiology.

[55]  Ø. Fluge,et al.  Pseudoprogression in high‐grade glioma , 2013, Acta neurologica Scandinavica. Supplementum.

[56]  Elizabeth Bullitt,et al.  A review of micro- and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MR , 2007, NeuroImage.

[57]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[58]  M. Westphal,et al.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.

[59]  Andrew E. Sloan,et al.  Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma , 2007, Journal of Neuro-Oncology.

[60]  M. Law,et al.  Magnetic resonance perfusion and permeability imaging in brain tumors. , 2009, Neuroimaging clinics of North America.

[61]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[62]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[63]  J. Menten,et al.  Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[64]  Ronald L. Wolf,et al.  Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. , 2009, Radiology.

[65]  J E Heiserman,et al.  Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.